Literature DB >> 16289982

High levels of protein expression using different mammalian CMV promoters in several cell lines.

Wei Xia1, Peter Bringmann, John McClary, Patrick P Jones, Warren Manzana, Ying Zhu, Soujuan Wang, Yi Liu, Susan Harvey, Mary Rose Madlansacay, Kirk McLean, Mary P Rosser, Jean MacRobbie, Catherine L Olsen, Ronald R Cobb.   

Abstract

With the recent completion of the human genome sequencing project, scientists are faced with the daunting challenge of deciphering the function of these newly found genes quickly and efficiently. Equally as important is to produce milligram quantities of the therapeutically relevant gene products as quickly as possible. Mammalian expression systems provide many advantages to aid in this task. Mammalian cell lines have the capacity for proper post-translational modifications including proper protein folding and glycosylation. In response to the needs described above, we investigated the protein expression levels driven by the human CMV in the presence or absence of intron A, the mouse and rat CMV promoters with intron A, and the MPSV promoter in plasmid expression vectors. We evaluated the different promoters using an in-house plasmid vector backbone. The protein expression levels of four genes of interest driven by these promoters were evaluated in HEK293EBNA and CHO-K1 cells. Stable and transient transfected cells were utilized. In general, the full-length human CMV, in the presence of intron A, gave the highest levels of protein expression in transient transfections in both cell lines. However, the MPSV promoter resulted in the highest levels of stable protein expression in CHO-K1 cells. Using the CMV driven constitutive promoters in the presence of intron A, we have been able to generate >10 microg/ml of recombinant protein using transient transfections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289982     DOI: 10.1016/j.pep.2005.07.008

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  16 in total

1.  Isotope labeling in mammalian cells.

Authors:  Arpana Dutta; Krishna Saxena; Harald Schwalbe; Judith Klein-Seetharaman
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Large-scale transfection of mammalian cells for the fast production of recombinant protein.

Authors:  Phuong Lan Pham; Amine Kamen; Yves Durocher
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

3.  Effect of transfection strategy on growth factor overexpression by articular chondrocytes.

Authors:  Shuiliang Shi; Scott Mercer; Stephen B Trippel
Journal:  J Orthop Res       Date:  2010-01       Impact factor: 3.494

4.  Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.

Authors:  Kathlyn Santos; Cindy M P Duke; Sol M Rodriguez-Colon; Anthony Dakwar; Shongshan Fan; Michael C Keefer; Howard J Federoff; John G Frelinger; William J Bowers; Stephen Dewhurst
Journal:  Vaccine       Date:  2006-11-15       Impact factor: 3.641

5.  CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sandra Motas; Virginia Haurigot; Miguel Garcia; Sara Marcó; Albert Ribera; Carles Roca; Xavier Sánchez; Víctor Sánchez; Maria Molas; Joan Bertolin; Luca Maggioni; Xavier León; Jesús Ruberte; Fatima Bosch
Journal:  JCI Insight       Date:  2016-06-16

6.  Effective isotope labeling of proteins in a mammalian expression system.

Authors:  Mallika Sastry; Carole A Bewley; Peter D Kwong
Journal:  Methods Enzymol       Date:  2015-10-23       Impact factor: 1.600

7.  Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells.

Authors:  Lanying Du; Guangyu Zhao; Lin Li; Yuxian He; Yusen Zhou; Bo-Jian Zheng; Shibo Jiang
Journal:  Biochem Biophys Res Commun       Date:  2009-05-05       Impact factor: 3.575

8.  CTCF binding to the first intron of the major immediate early (MIE) gene of human cytomegalovirus (HCMV) negatively regulates MIE gene expression and HCMV replication.

Authors:  Francisco Puerta Martínez; Ruth Cruz; Fang Lu; Robert Plasschaert; Zhong Deng; Yisel A Rivera-Molina; Marisa S Bartolomei; Paul M Lieberman; Qiyi Tang
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

9.  Cre recombinase activity is inhibited in vivo but not ex vivo by a mutation in the asymmetric spacer region of the distal loxP site.

Authors:  Tania Arguello; Carlos T Moraes
Journal:  Genesis       Date:  2015-09-18       Impact factor: 2.487

10.  In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.

Authors:  Douglas W Schneider; Tara Heitner; Bruno Alicke; David R Light; Kirk McLean; Noboru Satozawa; Gordon Parry; Jeongsoo Yoo; Jason S Lewis; Renate Parry
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.